PBYI
Puma Biotechnology, Inc.5.67
-0.15-2.58%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A explains routine inventory build
Puma's slim Q&A zeroed in on the Q4 inventory build of $5.7 million and 343 bottles, which management framed as routine year-end stocking ahead of price hikes—a pattern since launch. Alan Auerbach and Maximo Nougues stressed Q1 will see the usual burn-off, aligning with lower quarterly guidance. Answers largely reaffirmed prepared remarks on NERLYNX demand and alisertib progress. No contradictions or fresh strategy shifts surfaced. Q1 burn-off looms large. Investors eye alisertib interim data in Q2.
Key Stats
Market Cap
285.72MP/E (TTM)
7.66Basic EPS (TTM)
0.74Dividend Yield
0%Recent Filings
8-K
Q4 revenue jumps, profitability holds
Puma Biotechnology reported Q4 2025 net product revenue of $59.9 million, up from $54.4 million, driving total revenue to $75.5 million versus $59.1 million prior year. Full-year net income hit $31.1 million on $228.4 million revenue, with cash at $97.5 million after slashing debt to $22.5 million. Profitability persists. 2026 guidance projects $10–13 million full-year net income amid alisertib trial data readouts.
10-K
FY2025 results
Puma Biotechnology posted FY2025 revenue of $228.4M, down slightly from $230.5M in FY2024, with U.S. NERLYNX product sales up 5.5% on higher volumes and pricing despite softer royalties from international partners, mainly China. Q4 drove momentum as domestic sales accelerated amid stable gross margins, though variable reserves climbed to 24% on payor mix shifts. R&D jumped 13% to $62M fueling alisertib trials in lung and breast cancers, while SG&A fell 12% to $71M post-legal wins. Debt slashed to $22.5M with $97.5M cash; covenants met. Single-product reliance risks NERLYNX erosion from generics.
10-Q
Q3 FY2025 results
Puma Biotechnology posted Q3 revenue of $54.5M, down 32% y/y from $80.5M on lower China royalties yet product sales held at $51.9M with U.S. volumes up 8% despite softer pricing. Operating income shrank to $9.6M from $22.1M as cost of sales halved to $12.2M but R&D climbed 27% to $15.9M on alisertib trials; diluted EPS fell to $0.17 from $0.41, reconciled to 50.9M shares. Cash from operations hit $27.4M YTD while debt dropped to $33.7M current (Athyrium notes at 12.99%, due 2026); liquidity stands at $94.4M. Debt covenants extended to April 2026. Patent fights rage in China.
8-K
Raises NERLYNX outlook
Puma Biotechnology reported Q3 2025 NERLYNX net product revenue of $51.9 million, down from $56.1 million last year due to lower China supply and higher gross-to-net deductions, yet U.S. sales rose 8% on bottle volume. GAAP net income hit $8.8 million. Cash stands at $94.4 million. Company raised full-year NERLYNX revenue outlook to $198–$200 million, signaling demand rebound. Alisertib trials advance.
8-K
Q2 profit on revenue jump
IPO
Employees
Sector
Industry
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
LSTA
Lisata Therapeutics, Inc.
2.05+0.01
NRIX
Nurix Therapeutics, Inc.
18.84-0.17
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
NUVB
Nuvation Bio Inc.
8.66+0.15
PBM
Psyence Biomedical Ltd.
1.53+0.05
PMCB
PharmaCyte Biotech, Inc.
0.95+0.01
PMVP
PMV Pharmaceuticals, Inc.
1.18-0.02
ZLAB
Zai Lab Limited
17.00-0.34
ZNTL
Zentalis Pharmaceuticals, Inc.
1.38-0.02